NO934320L - T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer - Google Patents

T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer

Info

Publication number
NO934320L
NO934320L NO934320A NO934320A NO934320L NO 934320 L NO934320 L NO 934320L NO 934320 A NO934320 A NO 934320A NO 934320 A NO934320 A NO 934320A NO 934320 L NO934320 L NO 934320L
Authority
NO
Norway
Prior art keywords
immune
cell receptor
therapeutic agents
related diseases
tcr
Prior art date
Application number
NO934320A
Other languages
English (en)
Norwegian (no)
Other versions
NO934320D0 (no
Inventor
Arthur Allen Vandenbark
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of NO934320D0 publication Critical patent/NO934320D0/no
Publication of NO934320L publication Critical patent/NO934320L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO934320A 1991-05-31 1993-11-29 T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer NO934320L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70802291A 1991-05-31 1991-05-31
US73561291A 1991-07-16 1991-07-16
PCT/US1992/004492 WO1992021367A1 (en) 1991-05-31 1992-06-01 T cell receptor peptides as therapeutics for immune-related disease

Publications (2)

Publication Number Publication Date
NO934320D0 NO934320D0 (no) 1993-11-29
NO934320L true NO934320L (no) 1994-01-27

Family

ID=27108005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934320A NO934320L (no) 1991-05-31 1993-11-29 T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer

Country Status (11)

Country Link
EP (1) EP0587735B1 (de)
JP (1) JPH07502977A (de)
AT (1) ATE189230T1 (de)
AU (1) AU674494B2 (de)
CA (1) CA2110055C (de)
DE (1) DE69230612T2 (de)
DK (1) DK0587735T3 (de)
ES (1) ES2144418T3 (de)
GR (1) GR3033318T3 (de)
NO (1) NO934320L (de)
WO (1) WO1992021367A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667967A (en) * 1990-05-01 1997-09-16 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor varible transcripts as disease related markers
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
ATE244299T1 (de) * 1992-12-18 2003-07-15 Molecular Rx Inc Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
GB9308581D0 (en) * 1993-04-26 1993-06-09 Univ Manitoba A method for induction of antigen-specific suppression of immune-response
AU6376194A (en) * 1993-05-14 1994-12-12 Dr. L. Willems-Instituut Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
EP0720622A1 (de) * 1993-09-22 1996-07-10 The Board Of Trustees Of The Leland Stanford Junior University Wechselwirkung zwischen t-zellrezeptoren und antigen in autoimmunkrankheiten
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EP1172376A1 (de) 1994-11-18 2002-01-16 Neurocrine Biosciences, Inc. Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
AU2651997A (en) * 1996-05-10 1997-12-05 Kirin Beer Kabushiki Kaisha T-cell receptor alpha-chain constant-region peptides, processes for producing the peptides, and use thereof
EP2322216A1 (de) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha Präventives oder therapeutisches Mittel mit einem IL-6-Antagonisten als Wirkstoff für durch sensibilisierte T-Zellen vermittelte Erkrankungen
EP2050814A1 (de) 2007-10-17 2009-04-22 Txcell Zusammensetzungen zur Behandlung von Multipler Sklerose
EP3122768A2 (de) * 2014-03-27 2017-02-01 Yeda Research and Development Co. Ltd. T-zell-rezeptor-cdr3-peptide und -antikörper

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
ES2062519T5 (es) * 1989-03-21 2003-07-16 Immune Response Corp Inc Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t.
IL95125A (en) * 1989-07-19 1995-07-31 Vandenbark Arthur Allen T cell peptides receive a method for their selection and preparation, and pharmaceutical preparations containing them
JPH06507384A (ja) * 1991-01-22 1994-08-25 ザ　イミューン　レスポンス　コーポレイション 特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法

Also Published As

Publication number Publication date
ES2144418T3 (es) 2000-06-16
GR3033318T3 (en) 2000-09-29
DE69230612D1 (de) 2000-03-02
CA2110055C (en) 2002-08-20
EP0587735A1 (de) 1994-03-23
JPH07502977A (ja) 1995-03-30
EP0587735A4 (de) 1995-05-03
DE69230612T2 (de) 2000-06-21
AU674494B2 (en) 1997-01-02
CA2110055A1 (en) 1992-12-10
DK0587735T3 (da) 2000-09-11
WO1992021367A1 (en) 1992-12-10
EP0587735B1 (de) 2000-01-26
NO934320D0 (no) 1993-11-29
ATE189230T1 (de) 2000-02-15
AU2147292A (en) 1993-01-08

Similar Documents

Publication Publication Date Title
NO934320L (no) T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer
NO920252D0 (no) T celle-reseptor peptider som legemiddel for autoimmun ogmalign sykdom
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
EP0330227A3 (de) Lösliche T-4 Derivate
EP0545016A1 (de) Zusammensetzung für das Einbringen von Nukleinsäure-Komplexen in höhere eukaryotische Zellen
EA200300824A1 (ru) Тиенил-, фурил-, пирролил- и дифенилсульфонамиды и их производные, модулирующие активность эндотелина
ATE175446T1 (de) Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung
Cronkite et al. Mechanism of protective action of glutathione against whole body irradiation.
ATE205537T1 (de) Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier
NO943653L (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
DE3751319D1 (de) VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN.
ATE94764T1 (de) Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung.
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
AU3991899A (en) Verotoxin b subunit for immunization
Billingham et al. “Adoptive” immunization of animals against skin isografts and its possible implications
ES8302457A1 (es) Un procedimiento para preparar soluciones acu0sas a base de una sal de sulfonamida acuosoluble, un potenciador de sulfo-namida y un aldehido.
Urquhart et al. Trial of high-titre human rubella immunoglobulin.
Bainbridge et al. Studies on transplantation immunity: I. The nature of the response to allogeneic 51Cr-labeled lymphoid cells and its relationship to homograft immunity
Inoue et al. Protective effects of anti-glycoprotein D monoclonal antibodies in murine herpetic keratitis
AU8501191A (en) Cross-reactive influenza a immunization
SE9402332D0 (sv) Igf-1
北原糺 Molecular mechanisms of vestibular compensation